Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models

BACKGROUND: Entinostat, a selective class I histone deacetylase inhibitor, has been reported to enhance the activity of cytotoxic agents and suppress expression of PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS). PROCEDURES: Entinostat was tested against three rhabdomyosarcoma cell lines using 96-hou...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Pediatr Blood Cancer
Glavni autori: Kurmasheva, Raushan T., Bandyopadhyay, Abhik, Favours, Edward, Del Pozo, Vanessa, Ghilu, Samson, Phelps, Doris A., Erickson, Stephen W., Peer, Cody J., Figg, William D., Smith, Malcolm A., Houghton, Peter J.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6685061/
https://ncbi.nlm.nih.gov/pubmed/31099166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.27820
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items